Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium
Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium.
Diabetes Care. 2016 Aug;39 Suppl 2:S260-7. doi: 10.2337/dcS15-3016.
Obesity is a growing global health concern, associated with a number of important comorbid conditions. It increases the risk of diabetes and contributes to development of cardiovascular disease. While the benefits of weight loss are well established, weight reduction remains a difficult-to-reach goal in overweight and obese individuals due to several metabolic and psychological factors. For many patients, lifestyle intervention is insufficient to achieve long-term weight loss, and additional options, such as pharmacotherapy, need to be considered. Besides the challenging enterprise of weight reduction, weight maintenance remains an even more crucial and outcome-determining aspect of weight management. This article focuses on the potential of currently available pharmacological strategies to support weight loss and maintenance goals in individuals at risk. Two pharmacotherapy types are considered: those developed primarily to induce weight loss and those developed primarily for blood glucose control that have a favorable effect on body weight. Finally, the potential of very low- and low-calorie diets combined with pharmacotherapy and pharmacological combination therapies are discussed, as well as emerging approaches in development.
肥胖是一个日益严重的全球健康问题，与许多重要的合并症有关。它会增加糖尿病的风险，并导致心血管疾病的发展。虽然减肥的好处已得到充分证实，但由于多种代谢和心理因素，超重和肥胖人群减肥仍然难以实现目标。对于许多患者来说，生活方式干预不足以实现长期减肥，需要考虑其他选择，如药物治疗。除了减肥这一具有挑战性的任务外，体重维持仍然是体重管理中更关键和决定结果的方面。本文重点介绍了目前可用的药理学策略在有风险的个体中支持减肥和维持目标的潜力。考虑了两种药物治疗类型：主要用于诱导减肥的药物和主要用于血糖控制但对体重有有利影响的药物。最后，还讨论了极低热量和低热量饮食与药物治疗和药物联合治疗相结合的潜力，以及正在开发中的新方法。
